Xtandi 80 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FSPG2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,021
Award facts
- Contract value 100% obligated
- $17,021.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 60 tablets of Xtandi 80 mg. This delivery order, valued at $17,021.36 with an ultimate completion date of November 25, 2025, was awarded on November 24, 2025, without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award was issued under DMS Pharmaceutical Group's indefinite delivery contract (IDC) established through the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to supply pharmaceutical products to Department of Defense medical facilities worldwide.
DMS Pharmaceutical Group holds a single-award IDC under the PPV-G GEN V program with a $499.999 billion ceiling value and a completion date of December 31, 2036, structured with a 30-month base period and three 30-month option periods. The contractor's established distribution capabilities encompass branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, positioning it as a critical supplier for military healthcare operations globally. Xtandi, an oncology treatment, reflects the specialized pharmaceutical requirements DMS Pharmaceutical Group routinely fulfills for the federal military medical system through its delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division.
Quick answers
Who was awarded contract SPE2DR26FSPG2?
SPE2DR26FSPG2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 24, 2025.
How much is contract SPE2DR26FSPG2 worth?
The government has obligated $17,021 on SPE2DR26FSPG2.
Is contract SPE2DR26FSPG2 an order under another contract?
Yes. SPE2DR26FSPG2 is a delivery order under SPE2DR25D9337, an indefinite delivery contract.
Was contract SPE2DR26FSPG2 competed?
The extent of competition for SPE2DR26FSPG2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award